🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalFrance ANSM — semaglutide availability and Sécurité sociale coverage

France ANSM — semaglutide availability and Sécurité sociale coverage

sophie_paris Wed, May 27, 2026 at 6:41 PM 3 replies 293 viewsPage 1 of 1
sophie_paris
Member
212
890
Nov 2024
Paris, FR
May 27, 2026 at 6:41 PM#1

Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about semaglutide, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

The condition it depends on

One condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

The practical version

Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

What I am not sure about

The question I want answered is whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg. I have searched first, so if this is covered somewhere point me at it and I will read it.

— sophie_paris · corrections welcome and will be edited into this post with credit
36 6SallyK_inj, CryptoCarl, MariaRD and 33 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
May 27, 2026 at 7:10 PM#2
sophie_paris said:
The dose-response is real but shallow at the top.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

35 5roxy_nash, tony_orlando, Dr.NephBHM_UK and 32 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
May 27, 2026 at 7:39 PM#3
sophie_paris said:
The dose-response is real but shallow at the top.

Pushing back on sophie_paris here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

34 4mark_tokyo, hans_munich, jason_sac26 and 31 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
May 27, 2026 at 8:08 PM#4

Short answer first, then the reasoning. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Last edited: May 28, 2026 at 2:08 AM
33 3TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 30 others
Reply Quote Save Share Report
MarkLI_maint
Member
534
2,345
Jun 2024
Long Island, NY
May 27, 2026 at 10:49 PM#5
sarah.morrison said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Happy to go further on any of that.

Last edited: May 28, 2026 at 3:49 AM
32 2bri_stats, pete_manc_UK, anna.melb_AU and 29 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register